Abstract
This Canadian hepatitis C model estimates economic burden of disease using Markov modeling to predict progression over 11 health states annually from 2001 to 2040. Incidence-based estimates help demonstrate the capability to determine cost-effectiveness of programs to prevent different proportions of incident cases. Benefits of prevention increase linearly with the number of incident cases prevented. The model forecasts annual health care costs for the treatment of HCV-related disease ranging from $103 to $158 million over time. Health care costs attributable to 2001 incidence cohort are forecast at $14.6 million for prevention. The increasing cost of HCV provides a framework for further analysis and implementation of long-term policies aimed at appropriate allocation of resources for health in Canada.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zou S, Tepper M, Giulivi A (2000) Current status of hepatitis C in Canada. Can J Public Health 91:S10–S15
World Health Organization (1999) Global surveillance and control of hepatitis C—report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 6:35–47
Health Canada (2001) A cost of illness study of the hepatitis C virus infection in Canada: a report to the Blood Borne Pathogens Division, Health Canada. Institute of Health Economics: Edmonton.
Zou S, Tepper M, El Saadany S (2000) Prediction of hepatitis C burden in Canada. Can J Gastroenterol 14:575–580
Briggs A, Sculpher M (1998) Introducing Markov models for economic evaluation. Pharmacoeconomics 13:397–409
Hartunian N, Smart C, Thompson M (1980) Incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke. Am J Public Health 70:1249–1260
Berk A, Paringer L, Mushkin SJ (1978) The economic cost of illness fiscal 1975. Med Care 16:785–790
Henke KD, Behrens CS (1986) The economic cost of illness in the Federal Republic of Germany in the year 1980. Health Policy 6:119–143
Drummond M (1992) Cost of illness studies: a major headache? Pharmacoeconomics. 2:1–4
Koopmanschap MA (1998) Cost-of-illness studies: useful for health policy? Pharmacoeconomics 14:143–148
Van Doorslaer E, Bouter L (1990) Assessing the economic burden of injuries due to accidents: methodological problems illustrated with some examples from the literature. Health Policy 14:253–265
Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S (2003) Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 14:1057–1063
Shiell A, Law MG (2001) The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy 58:121–131
Shiell A, Gerard K, Donaldson C (1987) Cost of illness studies: an aid to decision making? Health Policy 8:317–323
Bloom BS, Bruno DJ, Maman DY, Jayadevappa R (2001) Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 19:207–213
Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127:855–865
Wong JB, McQuillan GM, McHutchison JG, Poynard T (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90:1562–1569
Singer ME, Younossi ZM (2001) Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 111:614–621
Loubiere S, Rotily M, Moatti JP (2003) Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care 19:632–645
Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW et al. (1997) Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 127:866–874
Buti M, Casado MA, Fosbrook L, Wong JB, Esteban R (2000) Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 33:651–658
Seeff LB (1999) Natural history of hepatitis C. Am J Med 107:10S–15S
Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5:559–575
Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (1994) Guidelines for economic evaluation of pharmaceuticals. CCOHTA: Ottawa
Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473–481
Koopmanschap MA, van Ineveld BM (1992) Towards a new approach for estimating indirect costs of disease. Soc Sci Med 34:1005–1010
O’Brien BJ (1996) Economic evaluation of pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 34 [12 Suppl]:DS99–D108
Acknowledgements
For editorial assistance, the authors wish to acknowledge Natalie Hanna, BA, Communication Officer of the Statistics and Risk Assessment Section, Blood Safety Surveillance and Health Care Acquired Infections Division. Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada
Conflict of interest:
No information supplied
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El Saadany, S., Coyle, D., Giulivi, A. et al. Economic burden of hepatitis C in Canada and the potential impact of prevention. Eur J Health Econ 6, 159–165 (2005). https://doi.org/10.1007/s10198-004-0273-y
Issue Date:
DOI: https://doi.org/10.1007/s10198-004-0273-y